Citius Oncology, Inc. (CTOR) vs Lifecore Biomedical, Inc. (LFCR)

Citius Oncology, Inc. and Lifecore Biomedical, Inc. are both Drug Manufacturers Specialty & Generic companies. Lifecore Biomedical, Inc. is the larger, with a market value of $162.4M against $97.6M — 1.7× the size. Citius Oncology, Inc. has the higher net margin (0.00% vs −37.5%) and the lower return on invested capital (−67.2% vs −2.80%). Across the 12 metrics below, Lifecore Biomedical, Inc. leads on 7 and Citius Oncology, Inc. on 5.

Valuation

Metric CTOR LFCR Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.14
P/S n/m 1.32 2.25
P/B 2.81 n/m 1.90
Price to free cash flow n/m n/m 16.54
EV/EBITDA n/m n/m 12.29
EV/Sales n/m 2.73 2.56
Earnings yield (44.76%) (23.10%) (2.99%)
Free cash flow yield (28.37%) (3.21%) 0.00%

Profitability

Metric CTOR LFCR Drug Manufacturers Specialty & Generic median
Gross margin — 26.86% 53.94%
Operating margin 0.00% (6.89%) 0.00%
Net margin 0.00% (37.54%) 0.00%
Free cash flow margin 0.00% (4.24%) 0.00%
Return on equity (126.58%) 201.15% (0.40%)
Return on assets (45.20%) (19.32%) (3.32%)
Return on invested capital (67.15%) (2.80%) 0.00%

Growth

Metric CTOR LFCR Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) — (10.03%) 10.01%
EPS growth (last fiscal year) (9.68%) (439.33%) —
Revenue growth, 5-year CAGR — (4.24%) 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CTOR LFCR Drug Manufacturers Specialty & Generic median
Debt to equity 0.50 11.50 0.05
Current ratio 0.73 3.87 2.31
Net debt to EBITDA (0.40) (15.59) 0.85

Dividend

Metric CTOR LFCR Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio — 0.00 0.00

Size

Metric CTOR LFCR Drug Manufacturers Specialty & Generic median
Market cap 97.63m 162.39m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack